https://jnj-7706621inhibitor.c....om/a-great-investiga
Pharmacologic treatment of acromegaly is based upon assay-error strategy, the first-generation somatostatin receptor ligands (SRL) becoming the first-line therapy. Nevertheless, about 50% of clients don't react adequately to SRL. Our objective would be to assess the possible usefulness of various molecular markers as predictors of reaction to SRL. We utilized somato
Like
Comment
Share
